Prion diseases are rare neurodegenerative conditions associated with the conformational conversion of the cellular prion protein (PrP C ) into PrP Sc , a self-replicating isoform (prion) that accumulates in the central nervous system of affected individuals. The structure of PrP Sc is poorly defined, and likely to be heterogeneous, as suggested by the existence of different prion strains. The latter represents a relevant problem for therapy in prion diseases, as some potent anti-prion compounds have shown strain-specificity. Designing therapeutics that target PrP C may provide an opportunity to overcome these problems. PrP C ligands may theoretically inhibit the replication of multiple prion strains, by acting on the common substrate of any prion replication reaction. Here, we characterized the properties of a cationic tetrapyrrole [Fe(III)-TMPyP], which was previously shown to bind PrP C , and inhibit the replication of a mouse prion strain. We report that the compound is active against multiple prion strains in vitro and in cells. Interestingly, we also find that Fe(III)-TMPyP inhibits several PrP Crelated toxic activities, including the channel-forming ability of a PrP mutant, and the PrP C -dependent synaptotoxicity of amyloid-β (Aβ) oligomers, which are associated with Alzheimer's Disease. These results demonstrate that molecules binding to PrP C may produce a dual effect of blocking prion replication and inhibiting PrP C -mediated toxicity.
, an endogenous cell-surface glycoprotein, into PrP Sc , a self-propagating, infectious protein (prion). PrP Sc replicates by directly binding to PrP C , and causing its conformational rearrangement into new PrP Sc molecules 1 . A great deal of evidence indicates that PrP Sc may exist as an ensemble of conformers (referred to as prion strains), eliciting different neuropathological effects 2 . Prion strains represent a critical problem for treating prion diseases. In fact, several potent anti-prion compounds are strain-specific [3] [4] [5] . Moreover, acquisition of resistance to therapeutic treatments, reported in prion-infected cells and mice, has been attributed to the appearance of drug-resistant prion strains 6, 7 . An additional confounding factor for drug discovery in prion diseases is related to the pathogenicity of PrP Sc . It is becoming increasingly evident that PrP Sc is not neurotoxic per se, and instead requires functional PrP C at the neuronal surface to deliver its detrimental effects [8] [9] [10] . Thus, PrP C appears to play two crucial roles in prion diseases, by passively sustaining prion replication, and actively mediating PrP Sc toxicity. Analogously, several studies have shown that PrP C may act as a selective, high affinity and toxicity-transducing receptor for Aβ oligomers, which are thought to be responsible for the synaptotoxicity underlying the cognitive decline in Alzheimer's disease 11 . An additional study reported that PrP C may also mediate the cytotoxicity of other β -sheet-rich protein aggregates 12 . These data suggest that, in addition to PrP Sc , multiple disease-associated protein aggregates may use PrP C to deliver their detrimental effects. This conclusion has therapeutic relevance. Compounds targeting PrP C , and blocking its transducing activity, may provide potential benefits for prion diseases, and possibly other neurodegenerative disorders 13 . Various chemical classes have been reported to bind PrP C . However, a careful evaluation of data reproducibility, as well as consistency between binding affinity and biological activity, restricted the number to a few 14, 15 . Among these, an iron tetrapyrrole derivative [Fe(III)-TMPyP, Fe(III)-meso-tetra(N-methyl-4-pyridyl)porphine] was shown to interact with the C-terminal, structured domain of PrP C , and to inhibit prion replication in vitro and in cells 16, 17 . The compound, or highly similar porphyrins, also significantly prolonged survival in prion-infected mice [18] [19] [20] . In this study, in addition to reproducing and extend PrP C -binding and anti-prion properties of Fe(III)-TMPyP, we report unexpected evidence regarding the activity of this compound in different cell-based assays for PrP C -related toxicity.
Results

Fe(III)-TMPyP binds to mouse, recombinant PrP
C . The cationic tetrapyrrole Fe(III)-TMPyP ( Fig. 1A) was previously shown to bind human recombinant PrP C , and inhibit the replication of a mouse prion in vitro and in cells, by acting as a pharmacological chaperone for the native fold of the protein 17 . Here, we sought to , as assayed by equilibrium dialysis. A 50 μM aliquot of the indicated compounds and recombinant proteins were placed in the assay and sample chambers, respectively. The chambers were separated by a 5,000 molecular weight cut-off membrane. Samples were left to equilibrate at room temperature for 1 day with gentle rocking. The concentration of each compound was quantified using UV-visible spectroscopy with buffer background subtracted. Statistics (by student t-test) was as follow: for GN8, Buffer vs BSA, p = 0.233; Buffer vs PrP confirm directly that Fe(III)-TMPyP is also able to bind full-length, mouse recombinant PrP C . First, we employed equilibrium dialysis, a technique originally used to detect binding of Fe(III)-TMPyP to human PrP C . The assay is based on the ability of a small molecule to equilibrate between two chambers, one filled with just buffer (assay chamber), and the other containing the target protein (sample chamber), separated by a membrane permeable only to the small molecule. As expected, Fe(III)-TMPyP (10 μM) equilibrated equally between the two chambers when the sample chamber contained no polypeptide, or BSA (10 μM). Conversely, when mouse recombinant PrP C (10 μM) was added to the sample chamber, we observed a marked (>75%) decrease in the concentration of Fe(III)-TMPyP in the assay chamber, indicating that the compound interacted with PrP C (Fig. 1B) . No binding was observed for GN8, a small molecule originally claimed to bind PrP C 21 , but that also failed to bind recombinant PrP C in following studies 17 . Next, we employed dynamic mass redistribution (DMR), a label-free, biophysical technique previously employed to detect molecular interactions at the equilibrium (Fig. 1C ) 22, 23 . Recombinant, mouse PrP C was immobilized on the surface of a 384-well, label-free microplate by amine-coupling chemistry. The plate was then incubated for 3 hr at room temperature to obtain optimal binding conditions, before adding different concentrations of Fe(III)-TMPyP (0.1-500 μM). Binding to PrP C was monitored after an additional 30 min of incubation. We observed dose-dependent binding of Fe(III)-TMPyP to PrP C in the concentration range of 0.1-1 μM, after which binding appeared to saturate. Experimental controls, used to normalize the signals, included empty surfaces (built in each microplate well) and buffer injections. Interestingly, the affinity constant obtained by DMR (Kd = 0.63 μM) was highly consistent with the inhibitory concentration at 50% (IC50) of Fe(III)-TMPyP and closely related compounds against prion replication in cell cultures (0.5-1 μM) 16 . Finally, we employed SPR, another biophysical technique previously used to characterize association and dissociation constants in a kinetic manner (Fig. 1D) . Recombinant PrP C was immobilized on the surface of an SPR chip, as confirmed by binding of an anti-PrP antibody (not shown). We then monitored the association and dissociation of Fe(III)-TMPyP (0.1-10 μM) over the course of ~18 min. Non-specific interactions were accounted by subtracting signals from channels where only buffer was injected, or no polypeptides were immobilized. The sensorgrams were best fitted by a Langmuir binding model for a heterogeneous ligand, likely reflecting the presence of recombinant PrP C molecules immobilized in different orientations onto the chip surface. These analyses indicated a dissociation constant for the interaction of Fe(III)-TMPyP to recombinant PrP C of 1.21 μM. Once again, we failed to observe detectable binding (>100 μM) for GN8 (not shown). Collectively, these data confirmed that Fe(III)-TMPyP binds to recombinant mouse PrP C in the low micromolar range. Of note, both DMR and SPR analyses revealed that Fe(III)-TMPyP binds also to BSA, used in some experiment to monitor non-specific interactions, at concentrations around 10 μM (not shown).
Fe(III)-TMPyP inhibits the replication of different prion strains. It was previously reported that
Fe(III)-TMPyP inhibits the replication of the Rocky Mountain Laboratory (RML) prion strain in cells 16, 17 . Since the compound has been proposed to act as a pharmacological chaperone, stabilizing the native conformation of PrP C , its inhibitory effect should theoretically be observed against multiple prion strains. In order to test this hypothesis, we first employed N2a cells, a sub-clone of murine neuroblastoma cells, infected with the 22L mouse prion strain. 22L-N2a cells were exposed for 72 h to different concentrations of Fe(III)-TMPyP (1-10 μM), or vehicle control, and the levels of proteinase K (PK)-resistant PrP Sc were measured by Western blot. We confirmed that treatment with Fe(III)-TMPyP reduced 22L-prion loads in a dose-dependent fashion, with an IC 50 of 1.61 ± 0.79 μM (Fig. 2) . No cytotoxicity was observed at the active concentrations (not shown; lethal dose 50% was higher than 100 μM).
To confirm that Fe(III)-TMPyP exerts its anti-prion effects in a strain-independent fashion, we employed the protein misfolding cyclic amplification (PMCA) reaction, a widely established in vitro assay for evaluating the propagation of prions in a test tube (Fig. 3) 
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. The methodology is based on a PrP Sc -triggered conversion of PrP C by repetitive cycles of incubation and sonication. Brain lysates from transgenic (Tg) mice expressing ovine PrP (called Tg338) were used as a substrate for the amplification of scrapie prions, used as seeds (Dawson isolate). Different dilutions of scrapie (from 1:10 to 1:163, 840) were pre-incubated with Fe(III)-TMPyP (500 μM) or vehicle (control) and subjected to a single round of PMCA. The levels of PrP Sc in each sample were then estimated by detecting PK-resistant PrP molecules by Western blot. In control samples, we observed robust PrP Sc amplification at every dilution (Fig. 3A) . Conversely, in presence of Fe(III)-TMPyP, PrP Sc was barely detectable only at the lower dilution. We concluded that the compound exhibited a potent inhibitory activity toward the amplification of PrP Sc . To further substantiate this observation, we employed a PMCA assay specifically designed to rapidly test the inhibitory activity of small compounds. In this assay, 1:100 dilutions of bank vole-adapted prion strains are used as seeds for bank vole brain substrates, subjected to a single overnight PMCA round, in presence or absence of the test compound. By using this alternative PMCA protocol, we were able to generate a >10 fold amplification of PrP Sc in 16 hours. At first, we determined the amplification factor of an Italian vole-adapted scrapie strain in presence of Fe(III)-TMPyP (500 μM) or vehicle control (Fig. 3B) . In these conditions, Fe(III)-TMPyP showed strong inhibitory activity toward the amplification of vole-adapted PrP Sc (amplification factors dropped from 14.43 ± 3.47 to 1.46 ± 0.83). Of note, exposure to Fe(III)-TMPyP did not alter the detection of PK-resistant PrP molecules by Western blot, as evidenced by the similar levels of PrP Sc detected in the frozen (F) controls (Fig. 3B,  lanes 1 and 3) . We tested the molecule also against two additional bank vole-adapted scrapie strains, distinct from the Italian strain [namely, a UK strain, derived from the sheep isolate SCR1 25 , and vole-adapted CH1641 26 ]. Fe(III)-TMPyP (500 μM) showed a comparably potent inhibitory effect against the three different strains (not shown). Finally, we performed dose-response experiments to estimate the IC 50 of Fe(III)-TMPyP against the Italian vole-adapted scrapie strain (Fig. 3C ). We found that the compound was already active at low micromolar concentrations (IC 50 = 6.21 + /− 1.9 μM). However, statistical significance was observed only at higher concentrations (50-100 μM), possibly due to the high variability of the assay. Taken together, these data strongly supported the notion that Fe(III)-TMPyP exerts its anti-prion activity in a strain-independent fashion.
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Fe(III)-TMPyP inhibits the cytotoxic effects of a mutant PrP. We have previously reported that PrP C molecules carrying deletions or point mutations in the conserved central region (CR) are associated with a spontaneous ion channel activity that critically depends on the conserved polybasic sequence at the extreme N-terminus 27, 28 . These currents can be easily recorded by patch clamping techniques. Since Fe(III)-TMPyP binds directly to PrP C , we tested whether this compound could alter the ion channel activity of ∆CR PrP (deleted for residues 105-125), the most active among the channel-forming mutants. As expected, HEK293 cells expressing ΔCR PrP displayed large, spontaneous inward currents that were absent in cells expressing wild-type (WT) PrP (Fig. 4) . Importantly, the currents were dose-dependently silenced by treatment with Fe(III)-TMPyP (IC 50 = 1.7 μM). The compound showed no effects at the highest concentration (50 μM) in WT cells.
As a possible consequence of its channel-forming activity, expression of ∆CR PrP has been shown to hypersensitize various cultured cell lines to the toxicity of cationic antibiotics 29 . These include Zeocin, a member of the bleomycin/phleomycin family, and aminoglycoside G418. This peculiar property was previously exploited to develop a drug-dependent cellular assay (DBCA) for studying the toxicity of ∆CR PrP 30 . Here, we used the DBCA to confirm the inhibitory effect of Fe(III)-TMPyP. As expected, ΔCR-expressing HEK293 cells exposed to Zeocin (500 μg/mL; Fig. 5A ) or G418 (500 μg/mL; not shown) for 72 h showed strongly reduced viability (< 30%), as assayed by MTT. Consistent with patch-clamp recordings, co-treatment with Fe(III)-TMPyP (0.1-10 μM) produced a robust, dose-dependent rescue of antibiotic-induced cell death (IC 50 = 3.26 ± 2.12 μM; Fig. 5B ). The compound failed to rescue the non-specific cell death induced by high concentrations of Zeocin (up to 2 mg/mL) in WT cells (Fig. 5C ). Fe(III)-TMPyP was also not toxic to control cells (up to 50 μM) and did not significantly alter ΔCR PrP expression ( 
Fe(III)-TMPyP blocks the synaptotoxicity of Aβ oligomers. The interaction between PrP
C and Aβ oligomers has been shown to trigger a rapid, toxic signaling pathway involving the transient activation of the tyrosine kinase Fyn, and ultimately producing a dysregulation of NMDA receptors, excitotoxicity, and dendritic spine loss 11, 31, 32 . Therefore, we tested whether Fe(III)-TMPyP could also inhibit the toxicity of Aβ oligomers mediated by PrP C . In a first set of experiments, we exposed primary cultures of postnatal mouse hippocampal neurons to Aβ oligomers (3 μM) for 20 minutes. Consistent with previous studies 32 , we found that the oligomers induced a quick, transient and robust (~2 fold) increase of phosphorylated Fyn (Fig. 7A) . The phospho-SFK antibody used here detects pY416 in several SFKs, but previous studies demonstrated that PrP C -dependent activation of kinases is specific for Fyn 32 . Pre-incubation for 20 minutes with Fe(III)-TMPyP (10 μM) completely prevented Aβ effects, maintaining Fyn phosphorylation to normal levels (Fig. 7A) . As observed in cultured cells, the compound showed no effect on PrP C expression (Fig. 6B) . Consistent with previous reports 32 , no significant increase in Fyn phosphorylation was detected in hippocampal neurons derived from PrP knockout (KO) mice, upon treatment with Aβ oligomers and/or Fe(III)-TMPyP (Fig. 7B ). Next, we tested the ability of Fe(III)-TMPyP to block Aβ oligomer-dependent synaptotoxicity (Fig. 8) . Primary hippocampal neurons were incubated for 3 hours with Aβ oligomers (3 μM). Consistent with previous reports 33 , we observed a decrease of several post-synaptic markers, as evaluated by Western blot of the Triton-insoluble fractions. Post-synaptic markers affected by Aβ oligomer treatment included subunits of the glutamate receptors NMDA (GluN2A, GluN2B, decreased to 40.9 ± 7.5 and 42.1 ± 2.3%, respectively) and AMPA (GluA1 and GluA2, decreased to 57.8 ± 4.3 and 36.1 ± 4.9%), as well as the post-synaptic density protein 95 (PSD-95; reduced to 51.3 ± 6.3%). In absence of Aβ oligomers, the levels of these proteins were not significantly changed upon treatment with Fe(III)-TMPyP (not shown). However, pre-treatment with Fe(III)-TMPyP for 20 minutes prior to incubation with Aβ oligomers significantly rescued the levels of all the post-synaptic markers (GluN2A and GluN2B levels were increased to 97,7 ± 16,3 and 92,6 ± 15%; GluA1 to 108.5 ± 25.9 GluA2 both to 106.7 ± 28.4%; and PSD95 to 112.2 ± 18.6%). The level of a control protein (actin) was not affected by either Aβ oligomers or Fe(III)-TMPyP. Collectively, these data demonstrate that Fe(III)-TMPyP inhibits the synaptotoxic effects of Aβ oligomers mediated by PrP C .
Discussion
Mounting evidence suggests that PrP Sc may be an inconvenient pharmacological target 34 . Indeed, several molecules identified as potent anti-prion agents in cells, have proven to be strain-dependent, showing therapeutic efficacy in vivo only against specific prion strains 5, 35 . To further complicate the matter, poorly defined misfolded PrP intermediates, rather than fully aggregated PrP Sc isoforms, are emerging as potential pathological species in prion diseases 36, 37 . We and others have been interested to explore an experimental strategy that may overcome these problems by directly targeting PrP C 13,38 . Small molecules binding to PrP C with sufficiently high affinity could theoretically stabilize its tertiary structure enough to disfavor the generation of any misfolded state or pathogenic PrP conformer. Moreover, since they target the native precursors of prion-induced misfolding reactions, rather than the aggregated end-products, PrP C -directed compounds should theoretically be effective independently of the prion strain phenomenon. A similar strategy applied to transthyretin, a protein associated with familial amyloid polyneuropathy, recently led to the development of Tafamidis, an approved drug for these disorders 39, 40 . Multiple chemical classes have been reported in the literature to bind PrP C . These include tricyclic phenothiazines, 2,4-diarylthiazoles, quinacrine, a compound named GN8, pyridine-3,5-dicarbonitriles, tetrapyrroles, and few others 15, 41 . Some of these, such as quinacrine, have been shown to bind PrP C in a non-specific fashion 42 . Others, like GN8, have not been confirmed to be PrP C ligands in following publications (we also failed to detect binding of GN8 to mouse PrP C in this study) 17 . Additional molecules were shown to bind PrP C at biologically-irrelevant concentrations. For example, binding to PrP C for promazine or chlorpromazine was observed by using millimolar concentrations of compounds 43 . However, these molecules are effective against prion replication in cell cultures at low micromolar concentrations, making it difficult to reconcile their biological activity with their putative, PrP C -directed mode of action 44, 45 . In this study, we sought to characterized the biological properties of a synthetic, iron-complexed porphyrin named Fe(III)-TMPyP. This compound was reported to interact with a relatively large region in the C-terminal, structured domain of PrP C , in correspondence to a pocket near the C-terminus of helix-3 17 . Fe(III)-TMPyP was shown to act as a pharmacological chaperone for PrP C , lowering the ground state of its native conformation, and inhibiting prion-induced misfolding in vitro and in cell cultures. Importantly, binding affinity for PrP C and active concentrations against prion propagation were 17 . We also detected an interaction between Fe(III)-TMPyP and BSA when the compound was tested by DMR and SPR, at concentrations slightly higher than those active in biological assays. Curiously, this was not observed by equilibrium dialysis. The possible, non-specific interaction with such an abundant plasma protein, together with the unlikelihood that the compound may cross the blood brain barrier, could negatively affect the therapeutic potential of Fe(III)-TMPyP upon systemic administration. Therefore, extensive pharmacokinetic profiling, coupled to chemical optimization efforts, will be required to design effective drug-like derivatives of Fe(III)-TMPyP.
We also tested the hypothesis that Fe(III)-TMPyP inhibits prion propagation in a strain-independent manner. The compound was challenged against the 22L prion strain in neuroblastoma cells, and four different sheep prion strains by using two alternative PMCA protocols. We found comparable IC 50 values for the activity of Fe(III)-TMPyP in cells and PMCA (1.61 μM and 6.21 μM, respectively). However, the inhibitory effect of the compound was much less reliable in the PMCA assay (statistically significant effects were detected only above 50 μM). Reasons for such discrepancy could be related to the stability of the compound in brain lysates under heavy sonication conditions, or simply to the higher variability of the PMCA assays. In any case, these data confirm the ability of the compound to bind PrP C at biologically-relevant concentrations, and exert its inhibitory activity against multiple prion strains.
Based on the observation that Fe(III)-TMPyP is a PrP C ligand, we were prompted to test the possibility that this compound may exert specific effects on PrP C activity. Despite two decades of intense investigation, the physiological function of PrP C is still uncertain 10, 46 . However, several direct or indirect effects of PrP C expression have been described in cells and mice. One of these is the ability of WT PrP C to rescue the neurodegenerative phenotype caused by particular PrP mutants 47 . In an attempt to investigate the role of PrP C in synaptic function, and how this activity could be connected to prion neurotoxicity, we and others have studied mutant forms of PrP carrying deletions in the highly conserved central region of the protein 27, 48, 49 . One of these mutants, referred to as ΔCR PrP (Δ105-125), has been shown to be soluble, protease-sensitive, and to have the same cellular localization pattern of WT PrP C 50 . However, in contrast to PrP C , expression of ΔCR PrP in transgenic mice causes cerebellar degeneration and neonatal death 27 . The neurotoxic mechanism activated by ΔCR PrP may relate to its ability to induce ionic currents at the plasma membrane. These currents are the most likely cause of the hypersensitivity to cationic antibiotics observed in a variety of ΔCR PrP-expressing cells 29 . In vivo, ΔCR PrP currents alter the physiological homeostasis of glutamatergic synapses, causing the activation of an excitotoxic cascade, and early degeneration of the granule neurons in the cerebellum 51 . Importantly, the entire spectrum of detrimental effects caused by ΔCR PrP can be dose-dependently suppressed by the co-expression of WT PrP C , suggesting that the mutant and WT proteins could be interacting at a functional level 10 . ΔCR PrP has another intriguing property that suggests its relevance for PrP C biology. Its activity has been shown to be dependent on two stretches of poly-basic residues in the N-terminal, flexible tail of the protein (23-28 and 95-105) 28 . Strikingly, these two sites are also directly involved in the interaction between PrP C and Aβ oligomers, and at least two additional protein aggregates 12, 52 . Together, these data suggest the intriguing possibility that the aberrant activity of ΔCR PrP, and the neurotoxic signaling activated by Aβ oligomers, could be connected to the physiological function of PrP C 10,14 .
In this study, we show that Fe(III)-TMPyP blocks ΔCR PrP activity in a dose-dependent fashion in two different cellular assays. These included the suppression of ΔCR PrP-induced currents, as measured by whole-cell patch clamp, and the inhibition of the hypersensitivity to cationic antibiotics conferred by the mutant, as evaluated by DBCA. Moreover, we found that pre-incubation with Fe(III)-TMPyP protects primary hippocampal neurons to the Fyn-mediated, PrP C -dependent synaptotoxicity of Aβ oligomers. These protective effects of Fe(III)-TMPyP are somehow unexpected. In fact, the compound has been shown to bind a pocket located in the C-terminal domain of PrP C 17 . This region is far from the CR deletion, and opposite from the structural determinants of ΔCR PrP activity and Aβ binding sites, which are both located in the unstructured N-terminus. How does binding of Fe(III)-TMPyP in the C-terminus block the toxic activities of the PrP C flexible N-terminus? One possibility is suggested by several recent studies indicating that the C-terminal and N-terminal domains of PrP C may be functionally coupled, or even directly interact with each other [53] [54] [55] [56] . Therefore, Fe(III)-TMPyP could be acting as an allosteric inhibitor of PrP C , blocking the toxic activities elicited by the N-terminal tail. This possibility opens up intriguing opportunities to employ Fe(III)-TMPyP not only as a therapeutic agent, but also as an experimental tool to study the function of PrP C . In summary, we have employed multiple biochemical, biophysical and cell-based techniques to demonstrate that Fe(III)-TMPyP binds to PrP C , and acts as a strain-independent inhibitor of prion replication. Importantly, we also show that the compound blocks the aberrant channel-forming ability of mutant ΔCR PrP, and prevents the Equilibrium dialysis. Compounds were diluted from a 50 mM stock into 1 mM sodium acetate buffer (pH 5). One hundred microliters of 50 μM Fe(III)-TMPyP, or GN8, were placed in the assay chamber of a 96-Well Equilibrium DIALYZER plate (Harvard Apparatus, Holliston, MA), with a 5,000 molecular weight cut-off membrane. One hundred microliters of buffer, 50 μM recombinant PrP C or bovine serum albumin (BSA) were placed in the sample chamber. Recombinant PrP C (residues 23-230) was expressed and purified as described previously 57 . Samples were left to equilibrate at room temperature for 24 h with slow rocking. The concentration of each compound from the assay chamber was quantified using a UV-visible spectrometer (Biotek, Winooski, VT), with the appropriate buffer or protein background subtraction.
Dynamic Mass Redistribution (DMR).
The EnSight Multimode Plate Reader (Perkin Elmer, Waltham, MA) was used to carry out DMR analyses. Immobilization of full-length (residues 23-230), mouse recombinant PrP C (15 μL/well of a 2.5 μM PrP C solution in 10 mM sodium acetate buffer, pH 5) on label-free microplates (EnSpire-LFB high sensitivity microplates, Perkin Elmer) was obtained by amine-coupling chemistry. The interaction between Fe(III)-TMPyP, diluted to different concentrations in assay buffer (10 mM PO4, pH 7.5, 2.4 mM KCl, 138 mM NaCl, 0.05% Tween-20) and PrP C , was monitored after a 30 min incubation at room temperature. All the steps were executed by employing a Zephyr Compact Liquid Handling Workstation (Perkin Elmer). The Kaleido software (Perkin Elmer) was used to acquire and process the data.
Surface plasmon resonance (SPR).
Binding studies were performed using the ProteOn XPR36 Protein Interaction Array system (Bio-Rad, Hercules, CA). The binding of Fe(III)-TMPyP was monitored by immobilizing ~16,000 Resonance Units (RU) of recombinant PrP C on the surface of a sensor chip (GL-H chip, Bio-Rad) by amine-coupling chemistry. Compounds were perfused over the chip for 150 sec to allow association, followed by a buffer (10 mM PO4, pH 7.5, 2.4 mM KCl, 138 mM NaCl, 0.05% Tween-20) wash to monitor dissociation. The resulting sensorgrams (time course of resonance unit signal) were fitted using the ProteOn analysis software (Bio-Rad) to obtain the corresponding association and dissociation rate constants (k on and k off , respectively), and the equilibrium dissociation constant (K d ).
Western blots. Samples were diluted 1:1 in 2X Laemli sample buffer (2% SDS, 10% glycerol, 100 mM Tris-HCl pH 6.8, 0.002% bromophenol blue, 100 mM DTT), heated at 95 °C for 10 min, then analyzed by SDS-PAGE. Proteins were electrophoretically transferred to polyvinylidene fluoride (PVDF) membranes, which were then blocked for 20 min in 5% (w/v) non-fat dry milk in Tris-buffered saline containing 0.05% Tween-20. After incubation with appropriate primary and secondary antibodies, signals were revealed using enhanced chemiluminescence (Luminata, BioRad), and visualized by a Bio-Rad XRS Chemidoc image scanner (Bio-Rad).
PMCA. Two different versions of the PMCA reactions were used in this study. The first one was performed as described previously 24 , with minor modifications. Briefly, Tg338 brains used for substrate were perfused using PBS/5 mM EDTA, and frozen immediately. A 50 μl aliquot of 10% Tg338 brain homogenate, seeded with different dilutions of scrapie (Dawson isolate) were loaded onto 0.2-ml PCR tubes. Samples were incubated with 0.5 μl of PBS (not shown), DMSO or Fe(III)-TMPyP (at final concentration of 500 μM) and placed at 37-38 °C into a sonicating water bath without shaking. Tubes were positioned on an adaptor placed on the plate holder of the sonicator (model S-700MPX, QSonica, Newtown, CT, USA), and subjected to cycles of incubation (30 min) followed by a 20 s pulse of 150-220 watts sonication (at 70-90% of amplitude) for 48 hr. The detailed protocol for PMCA, including reagents, solutions and troubleshooting, has been published elsewhere 58 . The second PMCA assay was performed as described previously 59 , with minor modifications. Briefly, PMCA substrates were prepared using 2-3 month-old bank voles homozygous for methionine at codon 109 (Bv109M). Perfused brains were immediately homogenized in Conversion Buffer (PBS 1×, pH 7,4; 0.15 M NaCl; 1% Triton X) with mini-Complete protease inhibitor (Roche) as 10% w/v, and then stored at − 80 °C. Fe(III)-TMPyP (1-500 μM) or vehicle control were added to the PMCA substrate just prior to the in vitro amplification experiment. Seeds were prepared using brain tissue from Bv109M terminally affected with three different Bv109M-adapted PrP Sc strains, namely Italian, UK and CH1641, derived from the Italian sheep PrP Sc isolate SS7, the UK sheep PrP Sc isolate SCR1 25 , and the experimental PrP Sc isolate CH1641 26 . Tissues were homogenized in PBS (10% w/v), diluted 1:10 and 1:100 in PMCA substrate and either frozen at − 20 °C or immediately subjected to PMCA. Samples were processed for 32 continuous cycles of PMCA, consisting of 20 s pulse sonication at 80% power output using a Misonix S3000 sonicator, followed by incubation for 30 min at 37 °C. All samples were analyzed by PK digestion and Western Blotting as previously reported 60 . Blots were probed with anti-PrP monoclonal antibody SAF84 (a.a. 167-173 Bank vole PrP sequence; 1.2 μg/mL), followed by horseradish peroxidase-conjugated anti-mouse immunoglobulin (Pierce Biotechnology, Rockford, IL). Proteinase K (PK)-resistant PrP bands were visualized using the chemiluminescence method (SuperSignal Femto, Pierce), detected by the VersaDoc imaging system (Bio-Rad) and quantified by QuantityOne software (Bio-Rad). The amplification factor was calculated by quantifying the amount of PrP Sc in post-PMCA 1:100 diluted samples (Y) and in the 1:10 frozen dilution (X), taking into account the different dilution factor within the two, using the formula (Y/X) × 10. The amplification factor was then calculated as the mean value (± standard deviation) of independent samples.
Prion-infected neuroblastoma cells. N2a cells (a subclone of N2a cells infected with the 22L prion strain)
were propagated for 5-7 passages to stabilize PrP Sc levels. Cells were grown in culturing medium [Dulbecco's Minimal Essential Media (DMEM), 10% heat-inactivated fetal bovine serum (Δ56-FBS), Non-Essential Amino Acids (NEAA) and Penicillin/Streptomycin (Pen/Strep)]. To test anti-prion activity of Fe(III)-TMPyP, cells were plated on day 1 in 24-well plates at approximately 60% confluence, in presence or absence of relevant compound (usually at concentrations between 0.1 and 10 μM). On days 2 and 4, 100% medium was changed, adding fresh compound. On day 3, each well was split 1:2 in medium containing fresh compound. In order to avoid the use of trypsin, cells were detached by adding medium directly onto the surface of the well, and mechanically dissociated by pipetting gently for 10-15 times. On day 5, cells were collected by adding 100 μl (per well) of lysis buffer (PBS, pH 7.4, 0.5% NP-40, 0.5% TX-100, plus complete EDTA-free Protease Inhibitor Cocktail Tablets, Roche) directly into the well. Proteinase-K (PK) digestion was performed by incubating 100 μl of lysate in a shaking (450 rpm) thermomixer for 1 h at 37 °C with 10 μg/ml of PK. The reaction was stopped by adding 2 mM PMSF, followed by methanol (MeOH) precipitation (10:1 volume ratio of MeOH to sample; each sample incubated for 4 h at − 80 °C and then centrifuged at 14.000 rpm × 20 min at 4 °C). The resulting pellet (dried at room temperature to remove any residual MeOH) was boiled in Laemli sample buffer, and subjected to Western blotting. Blots were probed with 6D11 antibody (1:4000) followed by goat anti-mouse IgG (Pierce), and signals were revealed using enhanced chemiluminescence (Luminata, BioRad) and visualized by a Biorad XRS image scanner.
Patch clamping of HEK293 cells.
The spontaneous ion channel activity induced by the ΔCR PrP mutant in HEK293 cells was detected by whole-cell patch clamping as previously described 61, 62 . Borosilicate electrodes with an electrical resistance of 3-6 MΩ were used. Cells were visualized with the 40X objectives using an Olympus BX51WI microscope equipped with reflected fluorescence, as well as differential interference contrast observation systems. Experiments were conducted at room temperature with the following solutions: Internal: 140 mM Cs-glucuronate, 5 mM CsCl, 4 mM MgATP, 1 mM Na2GTP, 10 mM EGTA, and 10 mM HEPES (pH 7.4 with CsOH); External: 150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM glucose, and 10 mM HEPES (pH 7.4 with NaOH). Data were acquired using a Multiclamp 700B amplifier and pClamp 10 software (Molecular Devices, Foster City, CA), and sampled at 5 kHz with a Digidata 1440 (Molecular Devices). Data were analyzed off-line using the Clampfit 10 software (Molecular Devices).
Drug-Based Cell Assay (DBCA).
The DBCA was performed as described previously 29 , with minor modifications. Briefly, HEK293 cells expressing ΔCR PrP were cultured at ~60% confluence in 24-well plates on day 1. On day 2, cells were treated with 500 μg/mL of Zeocin and/or Fe(III)-TMPyP (0.1-10 μM) for 72 hr. Medium (containing fresh Zeocin and/or Fe(III)-TMPyP) was replaced every 24 hr. On day 5, cell medium was removed and cells were incubated with 1 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma Aldrich, St. Louis, MO) in PBS for 30 min at 37 °C. MTT was carefully removed, and cells were re-suspended in 500 μL of DMSO. Values for each well were obtained by measuring at 570 nm, using a plate spectrophotometer (Biotek).
Preparation of Aβ oligomers. Synthetic Aβ (1-42) peptide (Karebay Biochem., Rochester, NY) was dissolved in hexafluoro-2-propanol, incubated for 10 min in a bath sonicator at maximum power, centrifuged at 15.000 × g for 1 min, aliquoted, dried, and stored at − 80 °C. Before use, the dried film was dissolved using DMSO and diluted to 100 μM in F12 Medium (Invitrogen, Waltham, MA). Oligomers were obtained by incubating the peptide for 16 h at 25 °C. This preparation routinely produces oligomers that elute near the void volume of a Superdex 75 10/300 size exclusion column (GE Healthcare, Little Chalfont, UK), and that react with oligomer-specific antibody A11 33 . Final Aβ oligomer concentrations were considered as monomer equivalents, since the size of the oligomers is heterogeneous.
Cultured hippocampal neurons.
Primary neuronal cultures were derived from the hippocampi of 2-day-old postnatal mice, and cultured as described previously 63 . Neurons were plated on 35-mm dishes (500,000 cells/dish) pre-coated with 25 μg/mL poly-D-lysine (Sigma P6407) in B27/Neurobasal-A medium supplemented with 0.5 mM glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin (all from Invitrogen). Experiments were performed 12 days after plating. Neurons were pre-treated for 20 min with Fe(III)-TMPyP (10 μM) and then exposed for 20 mins or 3 hr to Aβ oligomers (3 μM). Triton-insoluble fractions (TIF) were analyzed by immunoblot with antibodies against phospho-SFK (Tyr 416) or Fyn. The phospho-SFK antibody detects pY416 in several SFKs, but previous studies showed that PrP C -dependent activation of kinases is specific for Fyn. Actin was used as loading control. Subcellular fractionation was performed as reported previously, with minor modifications. Neurons were homogenized using a Potter-Elvehjem homogenizer in 0.32 M ice-cold sucrose buffer (pH 7.4) containing 1 mM HEPES, 1 mM MgCl2, 10 mM NAF, 1 mM NaHCO3, and 0.1 mM PMSF in the presence of protease inhibitors (Complete mini, Roche Applied Science, Penzberg, Germany) and phosphatase inhibitors (PhosSTOP, Roche Applied Science). Samples were centrifuged at 13.000 × g for 15 min to obtain a crude membrane fraction. The pellet was re-suspended in buffer containing 150 mM KCl and 0.5% Triton X-100 and centrifuged at 100,000 × g for 1 hr. The final pellet, referred to as the Triton-insoluble fraction, was re-homogenized in 20 mM HEPES supplemented with protease and phosphatase inhibitors and then stored at − 80 °C or directly used in further experiments. Protein concentration in each sample was quantified using the Bradford assay (Bio-Rad), and proteins (5 μg) were then analyzed by Western blotting. Primary antibodies were as follow: anti-GluN2A and anti-GluN2B (both 1:2000; Invitrogen), anti-GluA1 and anti-GluA2 (both 1:1000; Millipore, Billerica, MA), anti-PSD-95 (post-synaptic density protein 95; 1:2000; Cayman Chemical, Ann Arbor, MI), and anti-actin (1:5000; Millipore). Western blots were analyzed by densitometry using Quantity One software (Bio-Rad). All experiments were repeated on at least 4 independent culture preparations (n = 4).
